⌕
Capricor Therapeutics · CAPR · Nasdaq
Tenet 51 · Mixed
Compare
$9.06−4.90%Market openTenet 51 · Mixed
$9.06−0.47 (−4.90%)
Market open · 15-min delayed · as of 10:57 AM ET· Nasdaq · USD

Capricor Therapeutics (CAPR) Stock

Capricor Therapeutics (CAPR) has a Tenet Score of 51 of 100 against 409 Healthcare peers, as of Nov 16, 2026.

Sources Company filings, market prices and computed by Tenet Filings, prices and TenetScore as of How we compute thisNot investment advice

Key stats

Market cap
$529.1M
share price × the latest quarter's diluted weighted-average share count (vendor)
Dividend yield
0.00%
reinvests all
52-week range
2.96 – 40.37
low → high
Tenet Score
51/100
Mixed · 409 Healthcare peers

Industry: Drugs · see every company filed here →

Capricor Therapeutics Inc scores 51/100. Mixed. Strongest on financial health and value, quality is the soft spot versus 409 Healthcare peers. Insufficient inputs: Tenet 51 is built from 3 of 4 pillars, from 30% of its inputs. The pillars showing a dash had no data.

Tenet Score · vs sector

n=409
51/ 100
Mixed
Fundamental composite — rates the business, not the timing.
Each metric's standing vs the company's own record is shown on the Statistics tab.
Value
69
Quality
12
Health
72
Growth
—

Factor grades

Grid rings: 25 · 50 · 75 · 100 percentile
Growth omitted — no data yet.
ValueCQualityFHealthBGrowth—MomentumC
A grade is a label over the shown score. Value/Quality/Health/Growth are sector percentiles; Momentum ranks 12−1 return across the equity universe — a lens, never folded into the Tenet Score.
Show the math →

Price

Loading chart…
P/E
—
Not meaningful: the company made a loss.
P/B
2.6×
cap ÷ Sep 30, 2026 book value, Nov 13, 2026 close
P/S
—
no P/S on file
ROE
−100%
TTM through Sep 30, 2026
Operating margin
—
no operating margin on file
Net margin
—
Not reported in the company's filings for this period.
Current ratio
6.77
Sep 30, 2026 balance sheet
Net debt / EBITDA
—
Not meaningful: EBITDA is zero or negative.
EPS CAGR 4y
—
This growth figure starts in a period outside the history your plan includes.

The whole report, at a glance · every card is a live peek, click any to open the section

About Capricor Therapeutics Inc

Capricor Therapeutics is a publicly traded (NASDAQ: CAPR) biotechnology company with a mission to develop groundbreaking therapies that make a meaningful impact on patients’ lives. Capricor is focused on the development of biologics, primarily cell and exos…

Composite computed Nov 16, 2026 · peer basis: Healthcare (n=409) · every glimpse links to its full section with sources · not investment advice.

ETF exposure

held by 39 US ETFs · top wrappers by weightSee all ETFs holding CAPR →

Similar-sized companies in Drugs

The 10 companies in this industry closest in market cap, as of Nov 13, 2026.

What sector and industry is Capricor Therapeutics in?

Capricor Therapeutics is in the Healthcare sector and the Drugs industry.

What is Capricor Therapeutics' Tenet Score?

Capricor Therapeutics' Tenet Score is 51 out of 100, ranked against 409 Healthcare peers as of Nov 16, 2026.

Install Tenet on your phone

Tenet home pageMethodology© 2026 Tenet Investing Inc.

Data from Intrinio and Financial Modeling Prep.